Video

Study questions necessity of postop laboratory studies after robotic prostatectomy

Author(s):

Urology Times staff

“I think as technology evolves, we as urologists need to continue to evolve and make changes to our practice,” says Kevin T. Keating, DO.

In this video, Matthew A. Rohloff, DO, and Kevin T. Keating, DO, discuss findings from the Urology Practice study, “Are Postoperative Laboratory Studies Following Robotic Assisted Radical Prostatectomy Necessary?” for which they served as study authors. Rohloff and Keating are urology residents at Metro Health – University of Michigan Health, Wyoming, Michigan.

Related Videos
3d rendered illustration - bladder | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Wayne Kuang, MD, answers a question during a Zoom video interview
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Related Content
Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
December 26th 2024

Top 10 BPH articles and videos of 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Investigators identify potential dual targets in prostate cancer
December 20th 2024

Investigators identify potential dual targets in prostate cancer

Hannah Clarke
“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
High omega-3, low omega-6 diet may slow prostate cancer progression
December 16th 2024

High omega-3, low omega-6 diet may slow prostate cancer progression

Hannah Clarke
From baseline to 1 year, the Ki-67 index decreased in the dietary intervention cohort by 15% and increased in the control cohort by 24%.
Adding CAN-2409 to radiation improves DFS in localized prostate cancer
December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke
“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.
© 2024 MJH Life Sciences

All rights reserved.